Windlas Biotech Board Approves Unaudited Q2 FY27 Results

Windlas Biotech Ltd's Board of Directors has approved the unaudited financial results for the quarter and half-year ended September 30, 2026. The board also accepted the resignation of Mr. Ashok Kumar Windlass as Whole-time Director and Director, citing succession planning. Concurrently, Mr. Ashok Kumar Windlass has been appointed as Senior Management Personnel, effective November 6, 2026. Additionally, Mr. Hitesh Windlass has been appointed as the Chairman of the Board, effective November 5, 2026. The company's statutory auditors, M/s J C Bhalla & Co, have issued a Limited Review Report on the financial results.